Document is current

Article History

Received: 19 May 2024

Accepted: 5 August 2024

First Online: 19 August 2024

Declarations

:

: All study protocols were approved by the Institutional Review Boards at each participating center in accordance with the Declaration of Helsinki. Each patient provided written informed consent for the research use of their specimens before enrollment.

: F.D. reports personal fees from AbbVie, Amgen, Astra Zeneca, BeiGene, Gilead, Incyte, Novartis, and Roche outside the submitted work. L.B. reports advisory roles for Abbvie, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Sanofi, Servier; as well as research funding from Bayer, Jazz Pharmaceuticals. A.H. reports travel fees outside of the submitted work from Jazz Pharmaceuticals. M.T. and P.S. declare no COI related to this work. E.J. reports current employment at AstraZeneca. H.D. declares consultancy with honoraria from AbbVie, AstraZeneca, Gilead, Janssen, Jazz, Pfizer, Servier, Stemline, Syndax and Clinical Research funding to the Institution from AbbVie, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio and Servier. J.E. reports participation in Advisory Boards of Abbvie, Novartis, Astellas, Jazz Pharmaceuticals, BMS-Celgene, Pfizer, Amgen and Research grants from Novartis and Jazz Pharmaceuticals. J.K. reports personal fees from BMS/Celgene, Takeda, Janssen, Abbvie, Sanofi, Pfizer and Jazz Pharmaceuticals outside the submitted work. M.H. reports research funding to institution from Abbvie, Servier, Astellas, BergenBio, Glycostem, Jazz Pharmaceuticals, Karyopharm, Loxo Oncology, Novartis, PinotBio, honoraria by Abbvie, Bristol Myers Squibb, Janssen, Jazz Pharmaceuticals, Pfizer, Qiagen, Servier, Sobi, and consultancy fees by AvenCell, Abbvie, Astellas, Glycostem, Janssen, LabDelbert, Miltenyi, Novartis, Pfizer, PinotBio and Servier.